FDA lifts clinical hold on Repros' Proellex

06/13/2010 | Bloomberg Businessweek

The FDA approved Repros Therapeutics' request to conduct another trial of Proellex for use in reducing menstrual bleeding associated with uterine fibroids and endometriosis, lifting a clinical hold that was placed on the drug candidate last year because of liver toxicity. The drugmaker will test lower doses of Proellex on 12 women in a 10-week study comparing the drug with placebo.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA